Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 8;11(5):754. doi: 10.3390/ma11050754

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Targeted delivery of biotherapeutics from various nanoparticle formulations. (A) Surgical models of atherosclerosis lead to disturbed blood flow in ligated artery (LCA) vs. non-surgery control normal flow (RCA) resulting in overexpression of VCAM-1 used by targeted lipoparticles delivering miRNA. Targeted liposomes (VHPK-CCL anti-miR-712) resulted in decreased plaque size, collagen content, and other markers of inflammation (* p < 0.05). Reprinted (adapted) with permission from [51]; (B) PEI-mediated delivery of athero-protective miRNA encapsulated in silica microparticles targeting E-selectin reduced overall macrophage content within plaques, marking a reduced inflammatory response. Reprinted (adapted) from [60]; (C) Collagen-IV targeted PLGA NPs encapsulating anti-inflammatory cytokine IL-10 also localized to the plaque and reduced necrotic core size and generation of ROS. Reprinted (adapted) with permission from Kamaly, N. et al. Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis. ACS Nano 2016, 10, 5280–5292. Copyright 2016 American Chemical Society.